Global Peptide Vaccine Market and Clinical Pipeline Outlook 2020

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

For Latest Publication Visit Following Report Weblink

Global Peptide Cancer Vaccine Market and Clinical Trials Insight 2026

The outline of human vaccines had an incredible impact on global health system which resulted in intense reduction of mortality and morbidity caused by numerous diseases. Vaccines have led to some of the greatest public health achievements ever, including the eradication of naturally occurring smallpox from the globe and the near eradication of polio. This prophylaxis had a long journey through various roads and tunnels to become the humanities’ key achievement. Despite of the fact, that its mechanism of action remained unclear for centuries. New vaccines coined up in nineteenth century and after the expanded studies of infectious diseases and processed microorganism vaccination has become an intensive subject to be studied. By all the new advances towards the discovery and understanding of various diseases, our species was able to find a way to eradicate them.

In recent years peptides have emerged as the considerable vaccine candidate owning to their simple and cost efficient production and development process. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides represent an excellent starting point for the design of novel therapeutics. Several peptide vaccines are now being designed and are encountering phase I and phase II clinical trials.

Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.

Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment that could help pharmaceutical companies to generate more revenues and help patients to alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate cancer has been introduced in global market. This segment has tendency towards clinical trials as compared to marketed products. Most of the novel products are at different stages of clinical trials which would be introduced in global market in coming years. Biomarkers like Melanoma-Associated Antigen 1 (MAGE-1) for melanoma cancer vaccine and NY-ESO-1 for lung cancer are being developed. Their development requires state-of-art technology due to which they are still not available in market. But confidently these drugs are going to overcome the all hurdles and will become the best suitable candidates in drug market.

A persistent theme in recent peptide based therapeutics is to trigger adaptive antigen specific responses. The next generation drugs will be designed to deliver defined antigenic peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new advantages of their cytokine production in enhancing immune response.This is already evident that in ongoing clinical trials that the benefits of using such vaccines will be large however safety concerns with diseases like cancer and HIV are still under critical observations. With the growing knowledge of immunological mechanism of adjuvant action, including identifying the role of specific signaling pathways peptide based vaccines are going to become more attractive and more effective segment of therapeutics.

Although, the opinions of experts in this field are mixed, it is likely that with new product approvals and advanced research, the field of active peptide immunotherapy is self-assured for dramatic growth in the coming years. Using the gained knowledge and history of passive immunotherapy development as guiding tool, the peptides will revolutionize the market with modern treatment of varied diseases by the means of peptides vaccines.

“Global Peptide Vaccine Market and Clinical Pipeline Outlook 2020” Report Highlights:

Introduction and Classification of Peptide Vaccines
Designing and Production of Peptide Vaccine
Mechanism of Peptide Vaccine
Cancer Immunotherapy with Peptide Vaccine
Global Peptide Vaccine Clinical Pipeline by Company, Indication and Phase
Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
Majority vaccines in Preclinical Phase: 28 Vaccines
Global Peptide Vaccine Market Future Prospects

1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines

1.1 Introduction

1.2 Glimpse of Antiquity

2. Need of Peptide Vaccines

2.1 Why Peptides – More Desirable

2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines

3.1 On the Basis of Sources Obtained

3.2 On the Basis of Length

3.3 On the Basis of Epitopes

4. Designing and Production of Peptide Vaccine

4.1 Synthetic Peptide Vaccine

4.2 Selection of Peptide Antigen

4.3 Construction of Peptide Antigen

4.4 Chemical Synthesis of Peptide Vaccine

4.4.1 Solution Phase Synthesis (SPS)

4.4.2 Solid Phase Peptide Synthesis (SPPS)

5. Mechanism of Peptide Vaccine

5.1 Induction of Immune Response

5.1.1 Factors Affecting T-Cell Stimulation

5.1.2 Factors Affecting B-cell Stimulation

5.1.3 Factors Affecting T-helper Cells

5.2 Delivery System for Peptide Vaccines

5.2.1 Immunostimulatory Adjuvants

5.2.2 Vaccine Delivery System

5.3 Multiple Antigen Peptide System (MAP)

5.3.1 Use of MAP for Foot-and-Mouth Disease

6. Cancer Immunotherapy with Peptide Vaccine

6.1 Peptides as Tumor Antigens

6.2 Immunotherapy with Peptide Vaccination

6.3 Therapeutic Evaluation of Peptide Vaccine

6.3.1 Prostate Cancer

6.3.2 Breast Cancer

6.3.3 Gastric Cancer

6.3.4 Lung Cancer

6.3.5 Pancreatic Cancer

7. Global Peptide Vaccine Market Overview

7.1 Peptide Vaccine – Does have Long and Secure Future?

7.2 Peptide Patents Insights

7.3 Peptide Vaccine Pipeline Overview

8. Global Peptide Vaccine Market Dynamics

8.1 Accelerative Parameters

8.1.1 Peptidomics

8.1.2 Advances in Vaccine Research

8.1.3 Stronger Clinical Pipeline

8.1.4 Emergence of Biologics in Cancer Therapy

8.2 Commercialization Challenges and Modifications

8.2.1 Funding and Legal Issues

8.2.2 Designing and Manufacturing Challenges

8.2.3 Route of Administration

8.2.4 Peptide Pharmacodynamics and Pharmacokinetics

9. Global Peptide Vaccine Market Future Perspectives

10. Global Peptide Vaccine Clinical Pipeline by Company, Indication and Phase

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-III

11. Discontinued and Suspended Peptide Vaccine Clinical Pipeline by Company, Indication and Phase

11.1 No Development Reported

11.2 Discontinued

11.3 Market Withdrawal

11.4 Suspended

12. Competitive Landscape

12.1 AFFiRiS

12.2 AlerGenetica

12.3 Anergis

12.4 Antigen Express

12.5 Apitope Technology

12.6 Araclon Biotech

12.7 Artificial Cell Technologies

12.8 Benovus Bio

12.9 Bionor Pharma

12.10 Circassia

12.11 Celgene Corporation

12.12 Galena Biopharma

12.13 Immatics biotechnologies

12.14 Immune Design

12.15 ImmunoCellular Therapeutics

12.16 Invectys

12.17 ISA Pharmaceuticals

12.18 Lytix Biopharma

12.19 Medinet

12.20 Spotlight Innovation (Memcine Pharmaceuticals)

12.21 Merck Serono

12.22 OncoTherapy Science

12.23 Peptech

12.24 Peptinov

12.25 PeptiVir

12.26 Pharmasyntez

12.27 Renaptys Vaccines

12.28 Sumitomo Dainippon Pharma

12.29 TapImmune

12.30 Targovax

12.31 Vaxon Biotech

Figure 1-1: History of Vaccines

Figure 2-1: Peptides - Amino Acid and Proteins

Figure 2-2: Diversification of Vaccines

Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines

Figure 3-1: Classification of Peptide Vaccine by Source

Figure 3-2: Classification on Basis of Length

Figure 3-3: On the Basis of Epitopes

Figure 4-1: Synthetic Peptide Manufacturing Process

Figure 4-2: Selection of Synthetic Immunogenic Constructs

Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.

Figure 4-4: Fmoc Cleavage

Figure 4-5: Boc Cleavage

Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells

Figure 5-2: Delivery System Pathways by Adjuvants

Figure 5-3: Liposome and the Modes of Chemically Different Antigen Incorporation.

Figure 6-1: TAAs on the Basis of Tissue Distribution

Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells

Figure 6-3: Mechanism of Action of Sipuleucel-T

Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies

Figure 6-5: Peptides Applied in Treating Cancer

Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020

Figure 7-2: Approved Peptide Drugs

Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 7-5: Global - Active and Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-6: Global - Active and Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 8-1: Global - Peptide Market Favorable Parameters

Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges

Figure 8-3: Routes of Administration

Figure 12-1: Anergis – Clinical Pipeline

Figure 12-2: Apitope Technology – Clinical Pipeline

Figure 12-3: Benovus Bio – Clinical Pipeline

Figure 12-4: Bionor Pharma – Clinical Pipeline

Figure 12-5: Circassia – Clinical Pipeline

Figure 12-6: Celgene - Clinical Pipeline

Figure 12-7: Galena Biopharma - Clinical Pipeline

Figure 12-8: Immatics Biotechnologies - Clinical Pipeline

Figure 12-9: Immune Design – Clinical Pipeline

Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline

Figure 12-11: Invectys – Clinical Pipeline

Figure 12-12: ISA Pharmaceuticals – Clinical Pipeline

Figure 12-13: Lytix Biopharma - Clinical Pipeline

Figure 12-14: Merck Serono – Clinical Pipeline

Figure 12-15: Onco Therapy Science – Clinical Pipeline

Figure 12-16: Peptinov - Clinical Pipeline

Figure 12-17: Sumitomo Dainippon Pharma – Clinical Pipeline

Figure 12-18: Tapimmune – Clinical Pipeline

Figure 12-19: Targovax - Clinical Pipeline

Figure 12-20: Vaxon Biotech - Clinical Pipeline

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Payment Request

Report Title:

Name:

Email address:

Job title:

Organisation:

Contact number:

Country:

Accept Terms & Conditions And Privacy Policy

Global Peptide Vaccine Market and Clinical Pipeline Outlook 2020

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Need custom market research solution? We can help you with that too.

About us

Quick links

Contact us

Stay Connected